This inventor holds 4 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Washington University. Active years: 2009-2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Ballwin, MO (US) (2009)
- St. Louis, MO (US) (2018 - 2021)
Company Filing History:
Years Active: 2009-2021
Title: Innovations in Cancer Treatment by Suwanna Vangveravong
Introduction
Suwanna Vangveravong is a prominent inventor based in St. Louis, MO (US), known for her significant contributions to cancer treatment through innovative drug development. With a total of four patents to her name, she has made remarkable strides in the field of oncology.
Latest Patents
Her latest patents focus on sigma-2 receptor ligand drug conjugates as antitumor compounds. These patents detail methods of synthesis and applications for treating various cancers, including pancreatic cancer and synovial sarcoma. The compounds described in her patents include a sigma-2 receptor-binding moiety and a ferroptosis-inducing moiety. One notable molecular species exhibits an IC value below 5 µM against human pancreatic cancer cells in vitro. In vivo studies have shown that administration of this species promotes shrinkage of pancreatic cancer tumors in murine models, leading to a remarkable 100% survival rate of experimental animals, compared to only 30% or 40% survival with control therapies.
Career Highlights
Suwanna Vangveravong is affiliated with Washington University, where she continues her research and development efforts. Her work is characterized by a strong focus on innovative approaches to cancer treatment, which has garnered attention in the scientific community.
Collaborations
She collaborates with esteemed colleagues, including William G Hawkins and Robert H Mach, to further advance her research initiatives.
Conclusion
Suwanna Vangveravong's innovative work in developing sigma-2 receptor ligand drug conjugates represents a significant advancement in cancer treatment. Her contributions are paving the way for new therapeutic options that could improve survival rates for patients battling cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile